MTOR and breast carcinoma: Moreover, the highly expressed miR-100 maintains the phenotype of tumor-associated macrophages by targeting mTOR to promote tumor metastasis in mice, while intratumoral injection with an miR-100 inhibitor and combined cisplatin therapy showed better benefits for breast cancer therapy [29].